|

Alectinib Clinical Trials

17 actively recruiting trials across 6 locations

Also known as: Alecensa, Open cohort

Pipeline

Phase 1: 1Phase 2: 7Phase 3: 1Phase 4: 1Phase 1/2: 2Phase 2/3: 2

Top Sponsors

  • Hoffmann-La Roche3
  • Cancer Research UK2
  • University Medical Center Groningen1
  • Ulrik Lassen1
  • The Netherlands Cancer Institute1

Indications

  • Cancer17
  • Lung Cancer6
  • Haematological Malignancy3
  • Neoplasia2
  • Tumors2

Other11 trials

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Phase 2
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
Phase 4
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Phase 2/3
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Phase 2/3
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
Phase 2
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Phase 2

Daphne, Alabama1 trial

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Southern Cancer Center

Phase 2

Glendale, Arizona1 trial

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Palo Verde Hematology Oncology

Phase 3

Duarte, California1 trial

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

City of Hope Comprehensive Cancer Center

Phase 2

Palo Alto, California1 trial

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Lucile Packard Children's Hospital

Phase 1/2

Stanford, California1 trial

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

Stanford University

Phase 1/2

Basking Ridge, New Jersey1 trial

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Memorial Sloan Kettering Basking Ridge (LimitedProtocol Activities)

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.